ARCH
vs
S
S&P TSX Composite Index (Canada)
ARCH
Over the past 12 months, ARCH has underperformed S&P TSX Composite Index (Canada), delivering a return of -56% compared to the S&P TSX Composite Index (Canada)'s +27% growth.
Stocks Performance
ARCH vs S&P TSX Composite Index (Canada)
Performance Gap
ARCH vs S&P TSX Composite Index (Canada)
Performance By Year
ARCH vs S&P TSX Composite Index (Canada)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Arch Biopartners Inc
Glance View
Arch Biopartners, Inc. operates as a biotechnology company. The company is headquartered in Toronto, Ontario. The firm is focused on the development of technologies that make a medical or commercial impact. Its lead drug candidate Metablok is formed to treat or prevent dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver or kidneys, which often results in organ damage or failure, including in the case of sepsis and corona virus disease-2019 (COVID-19). Its drug candidate also includes AB569, Borg and MetaMx. Its AB569 is a drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs and wounds. The Borg is a peptide-solid surface Interface for binding of peptides to solid metal and plastic surfaces to inhibit biofilm formation and to reduce corrosion. Its MetaMx is a synthetic molecules that target brain tumor initiating cells and invasive glioma cells.
